Stocks making the biggest moves premarket: Regeneron, Dominion Energy, Macy's & more

Premarket movers were driven by company-specific catalysts: Regeneron fell more than 11% after a late-stage skin cancer treatment missed goals, while Dominion Energy jumped over 12% on NextEra's all-stock acquisition announcement. Berkshire Hathaway disclosures lifted Macy's about 4% and Delta more than 1%, while pressure hit UnitedHealth after Berkshire trimmed some shares. AI and activism were also in focus, with ServiceNow up more than 4% on a BofA upgrade, Salesforce down 1% on a downgrade, and Coinbase/Robinhood weaker as Bitcoin sank below $77,000.

Analysis

This tape is less about fundamentals in isolation and more about capital recycling and perception shocks. Berkshire’s disclosures are the key signal: the market will likely over-index on the headline names, but the more durable effect is on cohorts exposed to the same decision framework—high-quality, cash-generative franchises with identifiable catalysts, versus structurally challenged consumer/healthcare names where a single data point can re-rate the multiple quickly. The biggest second-order beneficiary is not the disclosed buyers themselves, but the “Berkshire basket” of balance-sheet strength, pricing power, and durability that can attract follow-on demand from momentum and event-driven capital over the next 1-4 weeks.

The M&A and activist prints create a fork in the utility/healthcare complex. If the Dominion transaction is credible, regulated utilities with asset-heavy footprints should compress on consolidation hopes, but the real trade is that acquisition premium can force rerating in names with similar long-duration cash flows and defensive yield profiles. In healthcare, the failed oncology read-through is potentially more important than the one stock: it raises the bar for late-stage biotech where valuation depends on binary clinical outcomes, and could pressure adjacent names with concentrated pipeline risk until investors get more visibility on next catalysts.

AI is still splitting software into winners and laggards. The market is implicitly saying that AI exposure is not a monolith: companies where AI can expand margins or drive workload growth can rerate, while those perceived as at risk of workflow displacement face multiple compression even without near-term earnings damage. Crypto-linked stocks remain a separate beta expression, and the weekend BTC drawdown shows how fast leverage and sentiment unwind in names with retail ownership; that weakness can persist for several sessions if spot fails to reclaim key levels.

Key Decisions for Investors

• Long NOW / short CRM for a 2-6 week relative-value pair: buy the AI beneficiary vs. the AI-disrupted incumbent. Risk/reward favors expansion in NOW’s multiple if the market continues to pay for “AI augmentation,” while CRM likely faces repeated estimate cuts and de-rating risk.
• Buy DAL on 1-3 month horizon on follow-through from the Berkshire signal, but size modestly. The setup is less about near-term earnings and more about a credibility reset that can support multiple expansion if fuel prices stay contained; stop if the move fades back below the premarket gap within several sessions.
• Short a basket of high-beta biotech names with single-asset or late-stage trial dependency against BIO.B as the cleaner relative long. The REGN reaction is likely to spill into names where clinical disappointment can become a valuation event over the next 2-8 weeks.
• Use weakness in COIN/HOOD for a tactical 3-10 day short only if BTC fails to reclaim prior support. This is a fast beta trade, not a structural call; cover on any decisive crypto rebound because the underlying flow can reverse violently.
• Avoid chasing utility strength in D near the open; if you want exposure, prefer a merger-arb or spread expression rather than outright long. The upside is already partially captured in the headline, while regulatory/financing friction could narrow the spread quickly if deal terms are questioned.